Okogen, Inc., a clinical-stage biotechnology company developing therapies for infectious diseases, announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, a Phase 1/2 clinical trial evaluating Treyegen™ (OKG-0303) for the treatment of acute infectious conjunctivitis. The authorization advances the program into clinical evaluation in India and represents a key regulatory milestone for a therapy designed to address both viral and bacterial forms of the condition with a single treatment.
The EMERALD study will enroll more than 300 patients and evaluate safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy, with data expected later this year. This comprehensive assessment is critical because acute infectious conjunctivitis, commonly known as pink eye, is a highly prevalent condition that affects millions globally and is typically caused by either viruses or bacteria. Current treatment approaches often require physicians to make a presumptive diagnosis and choose between antiviral or antibacterial therapies, which can lead to delayed or inappropriate treatment. By evaluating a single investigational therapy that targets both pathogen types, the EMERALD study could generate evidence to simplify treatment decisions and improve patient outcomes.
Treyegen™ (OKG-0303) is an investigational ophthalmic therapy that combines ranpirnase, a host-directed antiviral, tobramycin, a broad-spectrum antibacterial agent, and oxymetazoline, which reduces ocular redness, into one formulation. This differentiated approach is designed to address the broad clinical presentation of acute infectious conjunctivitis, potentially offering physicians a comprehensive therapeutic option without the need for multiple prescriptions. Okogen believes this strategy could streamline care and reduce the burden on healthcare systems by providing a single therapy that covers the most common causes of the disease.
The CDSCO authorization also carries broader implications for Okogen's host-directed antiviral platform. The company is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Ophthalmology serves as the lead clinical proving ground, and success in the EMERALD study could validate the platform's potential across other areas, including pandemic preparedness and systemic infections. The company's strategy aims to apply clinical insights, formulation expertise, and manufacturing capabilities from ophthalmology to a wider portfolio of antiviral therapies. For more information, visit www.okogen.com. The full announcement, including downloadable images and bios, is available click here.
If the EMERALD study meets its endpoints, Treyegen™ could become the first single therapy specifically approved for both viral and bacterial acute infectious conjunctivitis, addressing a significant unmet need in ophthalmology. The data expected later this year will be closely watched by clinicians, investors, and public health officials, as it may signal a new era in the treatment of common ocular infections and further validate host-directed antivirals as a versatile therapeutic class.
